NewsOK Local Stocks
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Akebia Therapeutics (NQ: AKBA)
4.050 USD  -0.220 (-5.15%)
Official Closing Price  /  Updated: 6:54 PM EDT, Jul 16, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 791,800
Open 4.290
Bid (Size) 4.030 (5)
Ask (Size) 4.100 (2)
Prev. Close 4.270
Today's Range 4.050 - 4.290
52wk Range 4.050 - 10.73
Shares Outstanding 56,913,886
Dividend Yield N/A
Performance
YTD
-30.17%
-30.17%
1 Month
-8.58%
-8.58%
3 Month
-43.20%
-43.20%
6 Month
-34.04%
-34.04%
1 Year
-59.70%
-59.70%
Top News
More News
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care Partners
Akebia Therapeutics, Inc. (Nasdaq: AKBA) a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P.... Read More
from Business Wire News Releases
Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia in Japan
Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line... Read More
from Business Wire News Releases
More News
Read More
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
from Business Wire News Releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
Akebia Therapeutics to Participate in Upcoming Investor Conferences
from Business Wire News Releases
PBSM's Underlying Holdings Could Mean 15% Gain Potential
category ETFs
from ETF Channel
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
from Business Wire News Releases
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from Business Wire News Releases
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
from Business Wire News Releases
Akebia Therapeut Has Returned 29.2% Since SmarTrend Recommendation (AKBA)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.